In this episode of Biotech Bulls and Breakthroughs, host John Gagliano speaks with Annalee Armstrong, Senior Editor at BioSpace, about the current state of the biopharma industry. They discuss exciting developments in neurodegenerative diseases, the hype surrounding GLP-1 drugs, the future of oncology, the psychedelic drug market, the role of the FDA, and the impact of AI on drug discovery. Annalee emphasizes the need for certainty in the biotech industry and the importance of focusing on good science amidst the current uncertainties.📲 Follow BioSpace's Senior Editor Annalee Armstrong: https://www.linkedin.com/in/annalee-armstronghttps://www.biospace.com/annalee-armstrongIn this episode:🔹Alzheimer's is seeing exciting developments. 🔹 GLP-1 drugs currently overshadow other critical therapeutic areas. 🔹 The psychedelic drug market has potential but faces monetization challenges.🧭 Track upcoming catalysts: https://www.biopharmcatalyst.com/calendars/fda-calendar🎧 Listen to more episodes: https://www.biopharmcatalyst.com/podcast📈 See Sheff’s Watchlist: https://www.biopharmcatalyst.com/sheffs-trades📲 Follow BioPharmCatalyst: https://x.com/BPharmCatalyst📲 Follow Sheff: https://x.com/SheffStationDisclaimer: BioPharmCatalyst is not a registered investment advisory firm and the views on this podcast are not to intended to be financial advice. The stocks discussed in this podcast may be held in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions.

Ver todos los episodios